BIH Lecture | Jonathan Kimmelman: “Clinical Trials of New Drugs: Do Patients Benefit from Participating in Clinical Trials?”

Language

Part of the Lecture Series "Frontiers in Translational Medicine - Scientific and Structural Challenges" on key questions of translation in medicine.

This page is only available in English.

BIH Lecture

“Clinical Trials of New Drugs: Do Patients Benefit from Participating in Clinical Trials?”

At one time, patients and many physicians regarded clinical trial participation as a dubious proposition. Today, many physicians, medical centres and patients view trial participation as a means of obtaining the best possible care- particularly with difficult to treat disorders. What is the evidence to substantiate this claim? In his presentation, Prof. Kimmelman will parse the various benefits trial participation might offer patients. He will then present evidence of his research team has gathered for each. He will conclude by identifying key unresolved questions, and by describing some of the moral and policy implications of his analysis of trial benefit.

About the Speaker

Jonathan Kimmelman, PhD, is James McGill Professor of Biomedical Ethics at McGill University. His research group, STREAM (Studies in Translation, Ethics and Medicine) uses empirical and theoretical methods to understand the ethical, policy, and scientific dynamics of developing new drugs. Kimmelman received the Maud Menten New Investigator Prize (2006), a CIHR New Investigator Award (2008), a Humboldt Bessel Award (2014), and was elected a Hastings Center Fellow (2018). He has sat on various advisory bodies within the U.S. NHLBI and NIAID, served for four tours of duty on U.S. National Academies of Medicine committees, and chaired the International Society of Stem Cell Research Guidelines for Stem Cell Research and Clinical Translation revision task force 2015-16. His research has been covered in major media outlets, including NPR’s All Things Considered, STATNews, and Nature. Kimmelman is deputy editor at Clinical Trials, and associate editor at Med.